Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Journal article

O. Sartor, J. de Bono, K. N. Chi, K. Fizazi, K. Herrmann, K. Rahbar, S. T. Tagawa, L. T. Nordquist, N. Vaishampayan, G. El-Haddad, …

Journal of Urology, Vol.207(2)

2022

Abstract

lutetium 177

vipivotide tetraxetan

cancer radiotherapy

cancer survival

human

metastatic castration resistant prostate cancer

molecular imaging

Note

overall survival

progression free survival

protein expression

response evaluation criteria in solid tumors

9 Record Views

Title: Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Creators: O. Sartor
J. de Bono
K. N. Chi
K. Fizazi
K. Herrmann
K. Rahbar
S. T. Tagawa
L. T. Nordquist
N. Vaishampayan
G. El-Haddad
C. H. Park
T. M. Beer
A. Armour
W. J. Perez-Contreras
M. DeSilvio
E. Kpamegan
G. Gericke
R. A. Messmann
M. J. Morris
B. J. Krause
Publication Details: Journal of Urology, Vol.207(2)
Identifiers: 00225347; 991006034234602656
Academic Unit: Radiology
Language: English
Resource Type: Journal article